快而精医药

JP Morgan Raises Qiagen PT to $60 from $55, Maintains Overweight

Citigroup Maintains Neutral on Qiagen, PT Down to $55 from $55.4

Qiagen: Stifel Raises PT to $50 from $45, Maintains Hold Rating

Qiagen

QIAGEN N.V.'s Q4 Earnings Meet Estimates, Revenues Up Y/Y, Stock Down 0.9%

Qiagen Exceeds Q4 2025 Expectations with Strong Financial Performance

Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant(3 bearish vs 1 bullish).</li> <li>Most analysts rate QGEN Neutral, showing limited institutional optimism.</li></ul>

Key Factors

QIAGEN N.V. reported Q4 2025 adjusted EPS of 62 cents, meeting estimates and up 1.6% YoY with net sales of $540.4 million.QIAGEN N.V. completed a $500 million share repurchase in January 2026 and reported full-year 2025 net sales of $2.09 billion, up 5.7% YoY.JP Morgan raised Qiagen’s price target to $60 from $55 and maintained an Overweight rating, while Stifel raised its PT to $50 from $45 and maintained a Hold rating.Qiagen forecast 2026 net sales growth of at least 5% and adjusted EPS of at least $2.50, driven by growth in tuberculosis testing and diagnostics.

QGEN News